Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension Durability of Blood Pressure Reduction Out to 24 Months
Authors
Sadowski, JerzyBartus, Krzysztof
Kapelak, Boguslaw
Rocha-Singh, Krishna J.
Katholi, Richard E.
Witkowski, Adam
Kadziela, Jacek
Januszewicz, Andrzej
Prejbisz, Aleksander
Walton, Anthony S.
Sievert, Horst
Id, Dani
Wunderlich, Nina
Whitbourn, Robert
Rump, Lars Christian
Vonend, Oliver
Saleh, Andreas
Thambar, Suku
Nanra, Ranjit
Zeller, Thomas
Erglis, Andrejs
Sagic, Dragan
Bošković, Srdjan
Brachmann, Johannes
Schmidt, Martin
Wenzel, Ulrich O.
Bart, Bradley A.
Schmieder, Roland E.
Scheinert, Dierk
Boergel, Jan
Straley, Craig
Symplicity HTN-1 Investigators
Article (Published version)
Metadata
Show full item recordAbstract
Renal sympathetic hyperactivity is seminal in the maintenance and progression of hypertension. Catheter-based renal sympathetic denervation has been shown to significantly reduce blood pressure (BP) in patients with hypertension. Durability of effect beyond 1 year using this novel technique has never been reported. A cohort of 45 patients with resistant hypertension (systolic BP GT = 160 mm Hg on GT = 3 antihypertension drugs, including a diuretic) has been originally published. Herein, we report longer-term follow-up data on these and a larger group of similar patients subsequently treated with catheter-based renal denervation in a nonrandomized manner. We treated 153 patients with catheter-based renal sympathetic denervation at 19 centers in Australia, Europe, and the United States. Mean age was 57 +/- 11 years, 39% were women, 31% were diabetic, and 22% had coronary artery disease. Baseline values included mean office BP of 176/98 +/- 17/15 mm Hg, mean of 5 antihypertension medicati...ons, and an estimated glomerular filtration rate of 83 +/- 20 mL/min per 1.73 m(2). The median time from first to last radiofrequency energy ablation was 38 minutes. The procedure was without complication in 97% of patients (149 of 153). The 4 acute procedural complications included 3 groin pseudoaneurysms and 1 renal artery dissection, all managed without further sequelae. Postprocedure office BPs were reduced by 20/10, 24/11, 25/11, 23/11, 26/14, and 32/14 mm Hg at 1, 3, 6, 12, 18, and 24 months, respectively. In conclusion, in patients with resistant hypertension, catheter-based renal sympathetic denervation results in a substantial reduction in BP sustained out to GT = 2 years of follow-up, without significant adverse events. (Hypertension. 2011;57:911-917.)
Keywords:
hypertension / blood pressure / renal sympathetic denervationSource:
Hypertension, 2011, 57, 5, 911-917Funding / projects:
- Ardian, Inc.
DOI: 10.1161/HYPERTENSIONAHA.110.163014
ISSN: 0194-911X
WoS: 000289730200017
Scopus: 2-s2.0-79955477242
Collections
Institution/Community
VinčaTY - JOUR AU - Sadowski, Jerzy AU - Bartus, Krzysztof AU - Kapelak, Boguslaw AU - Rocha-Singh, Krishna J. AU - Katholi, Richard E. AU - Witkowski, Adam AU - Kadziela, Jacek AU - Januszewicz, Andrzej AU - Prejbisz, Aleksander AU - Walton, Anthony S. AU - Sievert, Horst AU - Id, Dani AU - Wunderlich, Nina AU - Whitbourn, Robert AU - Rump, Lars Christian AU - Vonend, Oliver AU - Saleh, Andreas AU - Thambar, Suku AU - Nanra, Ranjit AU - Zeller, Thomas AU - Erglis, Andrejs AU - Sagic, Dragan AU - Bošković, Srdjan AU - Brachmann, Johannes AU - Schmidt, Martin AU - Wenzel, Ulrich O. AU - Bart, Bradley A. AU - Schmieder, Roland E. AU - Scheinert, Dierk AU - Boergel, Jan AU - Straley, Craig AU - Symplicity HTN-1 Investigators PY - 2011 UR - https://vinar.vin.bg.ac.rs/handle/123456789/4283 AB - Renal sympathetic hyperactivity is seminal in the maintenance and progression of hypertension. Catheter-based renal sympathetic denervation has been shown to significantly reduce blood pressure (BP) in patients with hypertension. Durability of effect beyond 1 year using this novel technique has never been reported. A cohort of 45 patients with resistant hypertension (systolic BP GT = 160 mm Hg on GT = 3 antihypertension drugs, including a diuretic) has been originally published. Herein, we report longer-term follow-up data on these and a larger group of similar patients subsequently treated with catheter-based renal denervation in a nonrandomized manner. We treated 153 patients with catheter-based renal sympathetic denervation at 19 centers in Australia, Europe, and the United States. Mean age was 57 +/- 11 years, 39% were women, 31% were diabetic, and 22% had coronary artery disease. Baseline values included mean office BP of 176/98 +/- 17/15 mm Hg, mean of 5 antihypertension medications, and an estimated glomerular filtration rate of 83 +/- 20 mL/min per 1.73 m(2). The median time from first to last radiofrequency energy ablation was 38 minutes. The procedure was without complication in 97% of patients (149 of 153). The 4 acute procedural complications included 3 groin pseudoaneurysms and 1 renal artery dissection, all managed without further sequelae. Postprocedure office BPs were reduced by 20/10, 24/11, 25/11, 23/11, 26/14, and 32/14 mm Hg at 1, 3, 6, 12, 18, and 24 months, respectively. In conclusion, in patients with resistant hypertension, catheter-based renal sympathetic denervation results in a substantial reduction in BP sustained out to GT = 2 years of follow-up, without significant adverse events. (Hypertension. 2011;57:911-917.) T2 - Hypertension T1 - Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension Durability of Blood Pressure Reduction Out to 24 Months VL - 57 IS - 5 SP - 911 EP - 917 DO - 10.1161/HYPERTENSIONAHA.110.163014 ER -
@article{ author = "Sadowski, Jerzy and Bartus, Krzysztof and Kapelak, Boguslaw and Rocha-Singh, Krishna J. and Katholi, Richard E. and Witkowski, Adam and Kadziela, Jacek and Januszewicz, Andrzej and Prejbisz, Aleksander and Walton, Anthony S. and Sievert, Horst and Id, Dani and Wunderlich, Nina and Whitbourn, Robert and Rump, Lars Christian and Vonend, Oliver and Saleh, Andreas and Thambar, Suku and Nanra, Ranjit and Zeller, Thomas and Erglis, Andrejs and Sagic, Dragan and Bošković, Srdjan and Brachmann, Johannes and Schmidt, Martin and Wenzel, Ulrich O. and Bart, Bradley A. and Schmieder, Roland E. and Scheinert, Dierk and Boergel, Jan and Straley, Craig and Symplicity HTN-1 Investigators", year = "2011", abstract = "Renal sympathetic hyperactivity is seminal in the maintenance and progression of hypertension. Catheter-based renal sympathetic denervation has been shown to significantly reduce blood pressure (BP) in patients with hypertension. Durability of effect beyond 1 year using this novel technique has never been reported. A cohort of 45 patients with resistant hypertension (systolic BP GT = 160 mm Hg on GT = 3 antihypertension drugs, including a diuretic) has been originally published. Herein, we report longer-term follow-up data on these and a larger group of similar patients subsequently treated with catheter-based renal denervation in a nonrandomized manner. We treated 153 patients with catheter-based renal sympathetic denervation at 19 centers in Australia, Europe, and the United States. Mean age was 57 +/- 11 years, 39% were women, 31% were diabetic, and 22% had coronary artery disease. Baseline values included mean office BP of 176/98 +/- 17/15 mm Hg, mean of 5 antihypertension medications, and an estimated glomerular filtration rate of 83 +/- 20 mL/min per 1.73 m(2). The median time from first to last radiofrequency energy ablation was 38 minutes. The procedure was without complication in 97% of patients (149 of 153). The 4 acute procedural complications included 3 groin pseudoaneurysms and 1 renal artery dissection, all managed without further sequelae. Postprocedure office BPs were reduced by 20/10, 24/11, 25/11, 23/11, 26/14, and 32/14 mm Hg at 1, 3, 6, 12, 18, and 24 months, respectively. In conclusion, in patients with resistant hypertension, catheter-based renal sympathetic denervation results in a substantial reduction in BP sustained out to GT = 2 years of follow-up, without significant adverse events. (Hypertension. 2011;57:911-917.)", journal = "Hypertension", title = "Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension Durability of Blood Pressure Reduction Out to 24 Months", volume = "57", number = "5", pages = "911-917", doi = "10.1161/HYPERTENSIONAHA.110.163014" }
Sadowski, J., Bartus, K., Kapelak, B., Rocha-Singh, K. J., Katholi, R. E., Witkowski, A., Kadziela, J., Januszewicz, A., Prejbisz, A., Walton, A. S., Sievert, H., Id, D., Wunderlich, N., Whitbourn, R., Rump, L. C., Vonend, O., Saleh, A., Thambar, S., Nanra, R., Zeller, T., Erglis, A., Sagic, D., Bošković, S., Brachmann, J., Schmidt, M., Wenzel, U. O., Bart, B. A., Schmieder, R. E., Scheinert, D., Boergel, J., Straley, C.,& Symplicity HTN-1 Investigators. (2011). Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension Durability of Blood Pressure Reduction Out to 24 Months. in Hypertension, 57(5), 911-917. https://doi.org/10.1161/HYPERTENSIONAHA.110.163014
Sadowski J, Bartus K, Kapelak B, Rocha-Singh KJ, Katholi RE, Witkowski A, Kadziela J, Januszewicz A, Prejbisz A, Walton AS, Sievert H, Id D, Wunderlich N, Whitbourn R, Rump LC, Vonend O, Saleh A, Thambar S, Nanra R, Zeller T, Erglis A, Sagic D, Bošković S, Brachmann J, Schmidt M, Wenzel UO, Bart BA, Schmieder RE, Scheinert D, Boergel J, Straley C, Symplicity HTN-1 Investigators. Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension Durability of Blood Pressure Reduction Out to 24 Months. in Hypertension. 2011;57(5):911-917. doi:10.1161/HYPERTENSIONAHA.110.163014 .
Sadowski, Jerzy, Bartus, Krzysztof, Kapelak, Boguslaw, Rocha-Singh, Krishna J., Katholi, Richard E., Witkowski, Adam, Kadziela, Jacek, Januszewicz, Andrzej, Prejbisz, Aleksander, Walton, Anthony S., Sievert, Horst, Id, Dani, Wunderlich, Nina, Whitbourn, Robert, Rump, Lars Christian, Vonend, Oliver, Saleh, Andreas, Thambar, Suku, Nanra, Ranjit, Zeller, Thomas, Erglis, Andrejs, Sagic, Dragan, Bošković, Srdjan, Brachmann, Johannes, Schmidt, Martin, Wenzel, Ulrich O., Bart, Bradley A., Schmieder, Roland E., Scheinert, Dierk, Boergel, Jan, Straley, Craig, Symplicity HTN-1 Investigators, "Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension Durability of Blood Pressure Reduction Out to 24 Months" in Hypertension, 57, no. 5 (2011):911-917, https://doi.org/10.1161/HYPERTENSIONAHA.110.163014 . .